Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxine and AEDs for Nodding Syndrome
NCT01730313Phase 2Withdrawn
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pyridoxine in nodding syndrome (4 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Change in the frequency of observed head nodding and other seizure activity at 12 weeks. Planned start Feb 2016; status: withdrawn.
02
Drugs
pyridoxine
03
Conditions
nodding syndrome
Beyond the preview
Go deeper on NCT01730313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730313.